A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma
-
Published:2023-06
Issue:6
Volume:21
Page:1466-1477
-
ISSN:1538-7836
-
Container-title:Journal of Thrombosis and Haemostasis
-
language:en
-
Short-container-title:Journal of Thrombosis and Haemostasis
Author:
Strijbis Viola J.F.ORCID, Romano Lorenzo G.R.ORCID, Cheung Ka Lei, Eikenboom JeroenORCID, Liu Ying PoiORCID, McCreary Andrew C., Leebeek Frank W.G.ORCID, Bos Mettine H.A.ORCID
Reference27 articles.
1. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?;Lenting;Blood,2017 2. The epidemiology of inhibitors in haemophilia A: a systematic review;Wight;Haemophilia,2003 3. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A;Eckhardt;Blood,2013 4. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, Windyga J, Llinas A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce GF; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020;26:1–158. 5. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors;Leissinger;N Engl J Med,2011
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|